183 related articles for article (PubMed ID: 12614191)
1. Review of ibandronate in the treatment of osteoporosis.
Chapurlat RD; Delmas PD
Expert Opin Pharmacother; 2003 Mar; 4(3):391-6. PubMed ID: 12614191
[TBL] [Abstract][Full Text] [Related]
2. Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review.
Reginster JY
Curr Pharm Des; 2005; 11(28):3711-28. PubMed ID: 16305506
[TBL] [Abstract][Full Text] [Related]
3. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.
Chesnut CH; Skag A; Christiansen C; Recker R; Stakkestad JA; Hoiseth A; Felsenberg D; Huss H; Gilbride J; Schimmer RC; Delmas PD;
J Bone Miner Res; 2004 Aug; 19(8):1241-9. PubMed ID: 15231010
[TBL] [Abstract][Full Text] [Related]
4. Beyond daily dosing: clinical experience.
Cooper C
Bone; 2006 Apr; 38(4 Suppl 1):S13-7. PubMed ID: 16520105
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacology of potent new bisphosphonates for postmenopausal osteoporosis.
Chapurlat RD
Treat Endocrinol; 2005; 4(2):115-25. PubMed ID: 15783248
[TBL] [Abstract][Full Text] [Related]
6. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
Schimmer RC; Bauss F
Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110
[TBL] [Abstract][Full Text] [Related]
7. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
Pyon EY
Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
[TBL] [Abstract][Full Text] [Related]
8. Ibandronate treatment for osteoporosis: rationale, preclinical, and clinical development of extended dosing regimens.
Epstein S
Curr Osteoporos Rep; 2006 Mar; 4(1):14-20. PubMed ID: 16527003
[TBL] [Abstract][Full Text] [Related]
9. Ibandronate: a review of its use in the management of postmenopausal osteoporosis.
Frampton JE; Perry CM
Drugs; 2008; 68(18):2683-707. PubMed ID: 19093707
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ibandronate given by intravenous injection once every 3 months.
Adami S; Felsenberg D; Christiansen C; Robinson J; Lorenc RS; Mahoney P; Coutant K; Schimmer RC; Delmas PD
Bone; 2004 May; 34(5):881-9. PubMed ID: 15121020
[TBL] [Abstract][Full Text] [Related]
11. Intravenous ibandronate: in the treatment of osteoporosis.
Croom KF; Scott LJ
Drugs; 2006; 66(12):1593-601; discussion 1602-3. PubMed ID: 16956306
[TBL] [Abstract][Full Text] [Related]
12. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE.
Chesnut CH; Ettinger MP; Miller PD; Baylink DJ; Emkey R; Harris ST; Wasnich RD; Watts NB; Schimmer RC; Recker RR
Curr Med Res Opin; 2005 Mar; 21(3):391-401. PubMed ID: 15811208
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates for prevention of postmenopausal osteoporosis.
Ravn P
Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
[TBL] [Abstract][Full Text] [Related]
14. Drug insight: Bisphosphonates for postmenopausal osteoporosis.
Chapurlat RD; Delmas PD
Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):211-9; quiz following 238. PubMed ID: 16932286
[TBL] [Abstract][Full Text] [Related]
15. A semimechanistic and mechanistic population PK-PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis.
Pillai G; Gieschke R; Goggin T; Jacqmin P; Schimmer RC; Steimer JL
Br J Clin Pharmacol; 2004 Dec; 58(6):618-31. PubMed ID: 15563360
[TBL] [Abstract][Full Text] [Related]
16. Ibandronate, an experimental intravenous bisphosphonate for osteoporosis, bone metastases, and hypercalcemia of malignancy.
Guay DR
Pharmacotherapy; 2006 May; 26(5):655-73. PubMed ID: 16637795
[TBL] [Abstract][Full Text] [Related]
17. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
Epstein S; Jeglitsch M; McCloskey E
Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
[TBL] [Abstract][Full Text] [Related]
18. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.
Bauss F; Russell RG
Osteoporos Int; 2004 Jun; 15(6):423-33. PubMed ID: 15205712
[TBL] [Abstract][Full Text] [Related]
19. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.
Ringe JD; Dorst A; Faber H; Ibach K; Sorenson F
Osteoporos Int; 2003 Oct; 14(10):801-7. PubMed ID: 14610641
[TBL] [Abstract][Full Text] [Related]
20. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
Thiébaud D; Burckhardt P; Kriegbaum H; Huss H; Mulder H; Juttmann JR; Schöter KH
Am J Med; 1997 Oct; 103(4):298-307. PubMed ID: 9382122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]